Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12

Br J Dermatol. 2019 Nov;181(5):886-887. doi: 10.1111/bjd.18437. Epub 2019 Sep 8.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adalimumab
  • Hidradenitis Suppurativa*
  • Humans
  • Treatment Outcome

Substances

  • Adalimumab